# Border Integration Rates

In pan-African research governance, does the rate of cross-border multi-national trials indicate progress toward continental regulatory harmonisation? This audit identified multi-country trials within Africa among 23,873 registrations using ClinicalTrials.gov API v2 collaborator and location fields through March 2026. Investigators reported the pan-African collaboration rate as the percentage of trials spanning two or more African nations. An estimated eight percent of African trials involved sites in multiple countries, compared to thirty-four percent in European multi-national trials. The most common cross-border corridors linked South Africa with Kenya and Uganda, reflecting PEPFAR-funded HIV research networks rather than sovereign African initiatives. The African Medicines Agency framework could accelerate harmonisation, but fewer than one hundred trials currently demonstrate true pan-continental regulatory integration. These findings indicate that Africa's research landscape remains fragmented by colonial-era borders rather than unified by shared disease burdens. Interpretation is limited by the inability to distinguish formal regulatory harmonisation from ad hoc multi-site collaborations.

## References

1. African Union. "Africa Health Strategy 2016-2030." AU Commission, Addis Ababa.
2. Ndounga Diakou LA, et al. "Mapping of clinical trials in sub-Saharan Africa." Trials. 2022;23:490.

## Note Block

- Type: research
- App: https://mahmood726-cyber.github.io/africa-e156-students/geographic-equity/dashboards/angle-19_border-integration-rates.html
- Code: https://github.com/mahmood726-cyber/africa-e156-students/blob/master/geographic-equity/code/angle-19-border-integration-rates.py
- Data: ClinicalTrials.gov API v2
- Date: 2026-04-05